Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
48.28
+0.30 (+0.63%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi
March 05, 2022
Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in...
Via
Talk Markets
AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants
March 03, 2022
AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA (NASDAQ: SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory...
Via
Benzinga
36 Stocks To Watch After Biden's First State of The Union Address
March 02, 2022
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped...
Via
Benzinga
Sanofi: Q4 Earnings Insights
February 04, 2022
Sanofi (NASDAQ:SNY) reported its Q4 earnings results on Friday, February 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Sanofi SA: An Expected Move Towards The $52.90
February 04, 2022
Today we can expect a move towards the $52.90 resistance, possibly further into the $54 price range, anticipating positive news.
Via
Talk Markets
Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
March 02, 2022
Sanofi SA (NASDAQ: SNY) has signed a collaboration with Adagene Inc (NASDAQ: ADAG) to advance two preclinical immuno-oncology candidates and an option to...
Via
Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
March 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
March 02, 2022
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...
Via
Benzinga
DarioHealth Enters Into Strategic Agreement With Sanofi U.S.
March 01, 2022
Novel Strategic Agreement focuses on commercial growth for Dario and the development of Digital Health Solutions on Dario’s platform.
Via
Talk Markets
Canada Approves First Plant-Based COVID-19 Vaccine
February 25, 2022
As Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc's (NYSE: GSK) COVID-19 vaccine finally heads to regulators, another shot using GSK's pandemic...
Via
Benzinga
BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market
February 24, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline...
Via
Benzinga
A Receding tide
February 23, 2022
Sanofi and GlaxoSmithKline have developed a new Covid-19 vaccine which they claim is 100% efficient.
Via
Talk Markets
Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data
February 23, 2022
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as...
Via
Benzinga
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women
February 18, 2022
GlaxoSmithKline plc (NYSE: GSK) has paused a late-stage trial of its respiratory syncytial virus (RSV) vaccine candidate in pregnant women based on safety...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO...
Via
Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
February 18, 2022
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab...
Via
Benzinga
Hopeful Golden Cross Forms On Sanofi's Chart
February 17, 2022
If history is any guide, there may be good fortune ahead for shares of Sanofi (NASDAQ:SNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could...
Via
Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
February 17, 2022
Can the formerly red-hot biotech segment return to its previous glory?
Via
Investor's Business Daily
3 Desirable Drug Stocks With Very Promising Pipelines
February 16, 2022
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.
Via
InvestorPlace
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
February 10, 2022
The
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Markets News for Tuesday
February 08, 2022
Oil stocks are up on huge gains.
Via
Talk Markets
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
February 06, 2022
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars
February 04, 2022
Sanofi SA's (NASDAQ: SNY)
Via
Benzinga
Earnings Scheduled For February 4, 2022
February 04, 2022
Companies Reporting Before The Bell • Brookfield Business (NYSE:BBU) is estimated to report earnings for its fourth quarter.
Via
Benzinga
A Preview Of Sanofi's Earnings
February 03, 2022
Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will likely...
Via
Benzinga
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
February 03, 2022
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,...
Via
FinancialNewsMedia
Exposures
COVID-19
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.